Full-Time

Human Resources Coordinator

Posted on 9/28/2025

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

No salary listed

New Haven, CT, USA

Hybrid

Hybrid role; prefers 1-2 days/week in New Haven office. Relocation not offered.

Category
People & HR (1)
Requirements
  • Bachelor’s degree required
  • 2-5 years of experience in a related role
  • Strong proficiency with Microsoft Office including Word (mail merge preferred), Excel (Vlookup preferred), PowerPoint, and Outlook; Experience with ADP and/or Greenhouse a plus.
  • Proficient at learning new systems quickly
  • Can-do and roll up your sleeves attitude
  • Exceptional organization and attention to detail, as well as a commitment to maintaining confidentiality
  • Excellent written and verbal communication skills
  • Effective team player with ability to engender confidence and credibility at all levels across the organization
  • Flexibility and ability to adapt to changing conditions
  • Strong analytical and problem-solving skills
  • Ability to multi-task and work in a very fast-paced and changing environment
Responsibilities
  • Talent Acquisition
  • Post roles on LinkedIn and other job boards.
  • Responsible for ensuring a positive candidate experience from application to onboarding
  • Monitor applicant flow in Greenhouse; when needed send application questions, correct/edit candidate information, proactively support recruiting team to ensure candidates continue to move through the process in a timely manner
  • Organize and schedule interviews across multiple time zones for candidates and team members. Must be able to arrange interview rooms, virtual meetings and provide necessary resources for a smooth interview process and positive candidate experience
  • Support recruiting team with ensuring an efficient and timely recruiting process including proactively helping to follow up on candidate communications, scheduling kickoff and debrief meetings, and any other support as needed
  • Support recruiting team with purchase orders and invoices
  • Utilize Greenhouse Recruitment and Greenhouse Onboarding to manage candidates, generate offer packages, reports and make continuous improvements to the system as needed
  • Total Rewards
  • Assist with administration of employee benefits plans including healthcare, life, disability, and other health and welfare benefits programs
  • Liaise with third-party benefits administrator, leave administrator, and payroll for employee-related questions, monitoring, communication, and program implementation
  • Responsible for initiating COBRA for departing employees to ensure they receive information in a timely manner
  • Approve new hire benefits selections in ADP
  • Reconcile benefits invoices and work with Finance to ensure accurate payment
  • Manage employee recognition program, including tracking of awards, communication with recipients and ensuring awards are distributed
  • Assist with year-end compensation planning, send out compensation letters and update systems accordingly
  • HR Operations
  • Process new hires and terminations in ADP
  • Responsible for arranging new hire onboarding and orientation schedule, including the orchestration of presentations and new hire activities
  • Oversee and follow onboarding and offboarding checklists for incoming/outgoing employees and contingent workers
  • Initiate and monitor background checks and I-9 process for candidates as well as contingent workers
  • Responsible for daily transaction changes including supervisor changes, title changes, and promotions / adjustments; ensure accuracy of organizational and reporting structures both in ADP and organizational charts
  • Create, update, and maintain accurate employee records and human resources related files (e.g. employee files, new hire and termination paperwork, job changes, reporting structure changes, promotions, and payroll changes)
  • Audit, maintain, and reconcile ADP data by pulling monthly reports for HR and Finance.
  • Provide support on research for projects, data audits, reporting needs and support on key presentations
  • Prepare termination packages as requested, including (as required) separation agreement, final benefit calculations, unemployment process instructions and COBRA information
  • Aid with the continuous audit of all Human Resources processes, policies, and programs to ensure compliance with country-specific employment laws
  • Act as first point of HR contact, fielding employee requests and routing to appropriate team member, and/or researching response for review before responding to employee directly
  • Support HR team with quarterly metrics data gathering, analysis and presentation
  • Serve as functional representative for purchase orders act as department liaison for contract submission and follow-through
  • Assist with the drafting and sending of HR related correspondence, preparation and distribution of documents and other materials as needed
  • Support payroll, review the payroll master file to capture new hires, leave of absence and changes
  • Provide support for company event and meeting coordination, as needed
  • Maintain company wide and functional organizational charts
  • Assist with ordering Invivyd swag
  • Other projects and support, as needed

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • DECLARATION Phase 3 trial fully enrolled with mid-2026 data readout for VYD2311 launch.
  • PEMGARDA revenue grew 31% sequentially in Q4 2025, validating antibody prophylaxis market demand.
  • Pipeline expansion into measles, RSV, and long COVID addresses multiple high-need viral indications.

What critics are saying

  • Low COVID community attack rates force 30% trial expansion, risking 6-9 month data delay.
  • Stock price below $1 triggers Nasdaq delisting risk, halting institutional investment and capital access.
  • Competing extended half-life COVID antibodies from AstraZeneca and Regeneron capture immunocompromised market share.

What makes Invivyd unique

  • Proprietary platform combines viral surveillance, predictive modeling, and antibody engineering for evolved immunity.
  • Targets immunocompromised populations underserved by traditional vaccines with monoclonal antibody prophylaxis.
  • FDA Fast Track designation for VYD2311 accelerates COVID-19 prevention development versus competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-5%

2 year growth

-1%
Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

TipRanks
Nov 17th, 2025
Invivyd Announces Common Stock Offering

Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.

Stock Titan
Aug 22nd, 2025
Invivyd Closes $57.5M Public Offering

Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.

INACTIVE